This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Randomized Controlled Trial  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2005;293:664-665.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although clinicians and patients were hoping that the recent rofecoxib debacle would be isolated to that drug alone, new clinical trial data now indicate that other nonsteroidal anti-inflammatory drugs (NSAIDs) may, like rofecoxib, raise the risk of heart attack and stroke. As patients and physicians wait for a clear analysis of the available data, they are left wondering about not only the safety of NSAIDs, but also the fate of clinical studies testing the drugs’ effectiveness for preventing other conditions.

In December, two government-sponsored studies were halted: the Adenoma Prevention with Celecoxib (APC) trial, a colorectal cancer study sponsored by the National Cancer Institute, and the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT), conducted by the National Institute on Aging.

Studies indicating that NSAIDs may raise cardiovascular risks have sparked a debate about risks vs benefits of using the drugs for treating disease or in prevention trials. (Photo . . . [Full Text of this Article]

WHAT TO DO WITH THE DATA?



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Buckstein et al.
Clin. Cancer Res. 2006;12:5190-5198.
ABSTRACT | FULL TEXT  

Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada
Rahme et al.
Rheumatology (Oxford) 2006;45:903-910.
ABSTRACT | FULL TEXT  

Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Fosslien
Annals of Clinical & Laboratory Science 2005;35:347-385.
ABSTRACT | FULL TEXT